Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
TVTX 
Travere Therapeutics Inc (TVTX)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: TVTX (5-star) is a STRONG-BUY. BUY since 88 days. Simulated Profits (101.56%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $41.5
1 Year Target Price $41.5
| 11 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 192.65% | Avg. Invested days 43 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.12B USD | Price to earnings Ratio - | 1Y Target Price 41.5 |
Price to earnings Ratio - | 1Y Target Price 41.5 | ||
Volume (30-day avg) 15 | Beta 0.89 | 52 Weeks Range 12.91 - 37.50 | Updated Date 12/15/2025 |
52 Weeks Range 12.91 - 37.50 | Updated Date 12/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -20.32% | Operating Margin (TTM) 15.12% |
Management Effectiveness
Return on Assets (TTM) -10.75% | Return on Equity (TTM) -410.78% |
Valuation
Trailing PE - | Forward PE 27.1 | Enterprise Value 3191540149 | Price to Sales(TTM) 7.15 |
Enterprise Value 3191540149 | Price to Sales(TTM) 7.15 | ||
Enterprise Value to Revenue 7.32 | Enterprise Value to EBITDA -5.67 | Shares Outstanding 89472327 | Shares Floating 77292459 |
Shares Outstanding 89472327 | Shares Floating 77292459 | ||
Percent Insiders 0.74 | Percent Institutions 117.3 |
About Travere Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2012-11-08 | President, CEO & Director Dr. Eric M. Dube Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 385 | Website https://www.travere.com |
Full time employees 385 | Website https://www.travere.com | ||
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.